Trial Profile
A Phase 1, Randomized, Partial-Blind, Placebo-controlled, Sequential Dose Group, Ascending, Multiple Dose Study of the Safety, Tolerability and Pharmacokinetics, With Food Effect, of CMX157 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Jun 2020
Price :
$35
*
At a glance
- Drugs Tenofovir exalidex (Primary)
- Indications Hepatitis B; Infections
- Focus Adverse reactions
- Sponsors ContraVir Pharmaceuticals; Hepion Pharmaceuticals
- 20 Apr 2017 According to a ContraVir Pharmaceuticals media release, results from this trial were presented at The International Liver Congress (ILC) 2017, the annual meeting of the European Association for the Study of the Liver (EASL).
- 18 Mar 2017 Results (n=10) presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 05 Dec 2016 Status changed from recruiting to completed.